Enzyme construct

Patent metadata

Field	Value
Publication number	US-9797009-B2
Application number	US-201314415533-A
Country	US
Kind code	B2
Filing date	Jul 18, 2013
Priority date	Jul 19, 2012
Publication date	Oct 24, 2017
Grant date	Oct 24, 2017

Abstract

The invention relates to methods using constructs comprising a helicase and an additional polynucleotide binding moiety. The helicase is attached to the polynucleotide binding moiety and the construct has the ability to control the movement of a polynucleotide. The constructs can be used to control the movement of polynucleotides and are particularly useful for sequencing polynucleotides.

First claim

The invention claimed is:

1. A method of characterizing a target polynucleotide, comprising:
(a) contacting the target polynucleotide with a transmembrane pore and a construct comprising a helicase and an additional polynucleotide binding moiety, wherein the helicase is attached to the additional polynucleotide binding moiety and the construct has the ability to control the movement of a polynucleotide, such that the construct controls the movement of the target polynucleotide through the pore; and
(b) taking one or more measurements as the polynucleotide moves with respect to the pore wherein the measurements are indicative of one or more characteristics of the target polynucleotide and thereby characterizing the target polynucleotide,
wherein the helicase and the additional polynucleotide binding moiety are covalently attached, are chemically attached or are genetically fused, and
wherein the additional polynucleotide binding moiety (a) comprises one or more helicases, (b) comprises one or more domains independently selected from helix-hairpin-helix (HhH) domains, eukaryotic single-stranded binding proteins (SSBs), bacterial SSBs, archaeal SSBs, viral SSBs, double-stranded binding proteins, sliding clamps, processivity factors, DNA binding loops, replication initiation proteins, telomere binding proteins, repressors, zinc fingers, and proliferating cell nuclear antigens (PCNAs), or (c) is derived from an exonuclease, polymerase, or topoisomerase.

2. The method according to claim 1 , wherein the helicase and the additional polynucleotide binding moiety are attached by one or more linkers or are attached by one or more linkers which are amino acid sequences.

3. The method according to claim 1 , wherein the additional polynucleotide binding moiety comprises one or more helicases.

4. The method according to claim 3 , wherein the helicase is of the same type as the one or more helicases of the additional polynucleotide binding moiety.

5. The method according to claim 3 , wherein the helicase is different from the one or more helicases of the additional polynucleotide binding moiety.

6. The method according to claim 3 , wherein the helicases are attached to one another using the same amino acid residue in each helicase.

7. The method according to claim 1 , wherein the additional polynucleotide binding moiety (b) comprises one or more domains independently selected from helix-hairpin-helix (HhH) domains, eukaryotic single-stranded binding proteins (SSBs), bacterial SSBs, archaeal SSBs, viral SSBs, double-stranded binding proteins, sliding clamps, processivity factors, DNA binding loops, replication initiation proteins, telomere binding proteins, repressors, zinc fingers, and proliferating cell nuclear antigens (PCNAs) or (c) is derived from an exonuclease, polymerase, or topoisomerase.

8. The method according to claim 1 , wherein the additional polynucleotide binding moiety is selected from those shown in Table 4 and variants thereof or the polymerase is Phi29 polymerase (SEQ ID NO: 62) or a variant thereof.

9. The method according to claim 3 , wherein the helicases are independently selected from superfamilies 1 to 6.

10. The method according to claim 3 , wherein the helicases are independently monomeric.

11. The method according to claim 3 , wherein the helicases are independently selected from Hel308 helicases, RecD helicases, Tral helicases, Tral subgroup helicases, XPD helicases, and variants thereof.

12. The method according to claim 9 , wherein:
(a) the Hel308 helicase comprises the amino acid motif Q-X1-X2-G-R-A-G-R (SEQ ID NO: 8), wherein X1 is C, M or L and X2 is any amino acid residue;
(b) wherein the RecD helicase comprises:
(i) the amino acid motif X1-X2-X3-G-X4-X5-X6-X7 (SEQ ID NO: 20), wherein X1 is G, S or A, X2 is any amino acid, X3 is P, A, S or G, X4 is T, A, V, S or C, X5 is G or A, X6 is K or R and X7 is T or S; and/or
(ii) the amino acid motif X1-X2-X3-X4-X5-(X6) 3 -Q-X7 (SEQ ID NO: 29), wherein X1 is Y, W or F, X2 is A, T, S, M, C or V, X 3 is any amino acid, X4 is T, N, or S, X5 is A, T, G, S, V or I, X6 is any amino acid and X7 is G or S;
(c) the Tral helicase or Tral subgroup helicase comprises:
(i) the amino acid motif H-(X1) 2 -X2-R-(X3) 5-12 -H-X4-H (SEQ ID NOs: 31-38), wherein X1 and X3 are any amino acid and X2 and X4 are independently selected from any amino acid except D, E, K and R; or
(ii) the amino acid motif G-X1-X2-X3-X4-X5-X6-X7-H-(X8) 6-12 -H-X9 (SEQ ID NOs: 39-45), wherein X1, X2, X3, X5, X6, X7 and X9 are independently selected from any amino acid except D, E, K and R, X4 is D or E and X8 is any amino acid; or
(d) the XPD helicase comprises:
(i) the amino acid motif X1-X2-X3-G-X4-X5-X6-E-G (SEQ ID NO: 50), wherein X1, X2, X5 and X6 are independently selected from any amino acid except D, E, K and R and wherein X3 and X4 is any amino acid residue; and/or
(ii) the amino acid motif Q-Xa-Xb-G-R-Xc-Xd-R-(Xe)3-Xf-(Xg)7-D-N-R (SEQ ID NO: 51), wherein Xa, Xe and Xg is any amino acid residue and wherein Xb, Xc and Xd are independently selected from any amino acid except D, E, K and R, and wherein Xf is D or E.

13. The method according to claim 12 , wherein (a) X2 in Hel308 helicase is A, F, M, C, V, L, I, S, T or P; (b) the Hel308 helicase is one of the helicases shown in Table 1 or a variant thereof having helicase activity; (c) the Hel308 helicase comprises (i) the sequence shown in SEQ ID NOs: 10, 13, 16, or 19 or (ii) a variant thereof having at least 80% sequence identity to SEQ ID NOs: 10, 13, 16, or 19 over the entire sequence and retaining helicase activity; (d) the Tral helicase comprises (i) the sequence shown in SEQ ID NO: 46, 87, 98, or 102 or (ii) a variant thereof having at least 80% sequence identity to SEQ ID NO: 46, 87, 98, or 102 over the entire sequence and retaining helicase activity; (e) X1, X2, X5 and X6 and/or Xb, Xc and Xd in the XPD helicase are independently selected from G, P, A, V, L, I, M, C, F, Y, W, H, Q, N, S and T; or (f) the XPD helicase comprises (i) the sequence shown in SEQ ID NO: 52 or (ii) a variant thereof having at least 80% sequence identity to SEQ ID NO: 52 over the entire sequence and retaining helicase activity.

14. The method according to claim 3 , wherein at least one of the helicases is modified to facilitate the attachment by the introduction of one or more non-native cysteine residues and/or one or more 4-azido-L-phenylalanine (Faz) residues.

15. The method according to claim 1 , wherein the one or more characteristics are selected from (i) the length of the target polynucleotide, (ii) the identity of the target polynucleotide, (iii) the sequence of the target polynucleotide, (iv) the secondary structure of the target polynucleotide, (v) whether or not the target polynucleotide is modified and (vi) whether or not the target polynucleotide is modified by methylation, by oxidation, by damage, with one or more proteins or with one or more labels, tags or spacers.

16. The method according to claim 1 , wherein the one or more characteristics of the target polynucleotide are measured by an electrical measurement, an optical measurement, a current measurement, an impedance measurement, a tunneling measurement and/or a field effect transistor (FET) measurement.

17. The method according to claim 1 , wherein the method comprises measuring the current passing through the pore as the polynucleotide moves with respect to the pore wherein the current is indicative of one or more characteristics of the target polynucleotide and thereby characterizing the target polynucleotide.

18. The method a

Assignees

• Oxford Nanopore Tech Ltd

Inventors

• Heron Andrew
• Clarke James
• Moysey Ruth
• Wallace Elizabeth Jayne
• Bruce Mark
• Jayasinghe Lakmal
• Caprotti Domenico
• Soeroes Szabolcs
• Mcneill Luke
• Misca Mihaela

Classifications

• C12Y306/04

  acting on acid anhydrides; involved in cellular and subcellular movement (3.6.4) · CPC title

• C12Q1/6869 Primary

  Methods for sequencing · CPC title

• C12N9/14

  Hydrolases (3) · CPC title

• C07K2319/00

  Fusion polypeptide · CPC title

• C12Q2521/513

  Winding/unwinding enzyme, e.g. helicase · CPC title